PBAC's latest decision on Baclofen: Recommended (2017). Considered for Treatment of severe chronic spasticity of cerebral origin, due to multiple sclerosis, due to spinal cord injury, or due to spinal cord disease, in patients who have failed to respond to oral antispastic agents or experienced unacceptable side effects.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Patients with severe chronic spasticity of cerebral origin (due to multiple sclerosis, spinal cord injury, or spinal cord disease) who have failed to respond to treatment with oral antispastic agents or experienced unacceptable side effects.
Therapy area
Neurology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Economic model
Cost-minimisation
ICER note
Not modelled — this was a minor submission for a new strength formulation with equivalent pricing to the existing baclofen 10 mg/5 mL listing; no economic evaluation was conducted.